Nifty
:
26178.70
Sensex
:
85063.34
-71.60 (-0.27%)
-376.28 (-0.44%)
Nifty
Sensex
:
:
26178.70
85063.34
-71.60 (-0.27%)
-376.28 (-0.44%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
72/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
2074.60
06-Jan-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2031.5
  •  2080.8
  •  2031.5
  •  2039.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  223376
  •  460686801.3
  •  2284.8
  •  1275.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 58,542.56
  • 56.97
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 56,743.83
  • 0.12%
  • 6.00

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.07%
  • 10.81%
  • FII
  • DII
  • Others
  • 20.73%
  • 17.01%
  • 2.73%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.83
  • 4.01
  • 4.77

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.05
  • 2.44
  • 7.54

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.49
  • 1.54
  • 10.03

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.58
  • 13.69
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.84
  • 3.06
  • 3.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.15
  • 11.93
  • 14.96

Earnings Forecasts:

(Updated: 03-01-2026)
Description
2024
2025
2026
2027
Adj EPS
37.11
71.5
81.12
95.9
P/E Ratio
55.90
29.02
25.57
21.63
Revenue
13145.8
14999
16377.5
18122.2
EBITDA
2379.61
3077.76
3535.38
4096.64
Net Income
1047.1
2172.31
2332.86
2706.01
ROA
6.89
13.49
16.03
P/B Ratio
6.62
5.03
4.27
3.72
ROE
12.54
19.4
18.78
18.95
FCFF
-1725.82
1078.98
1248.63
1594.78
FCFF Yield
-3.01
1.88
2.18
2.78
Net Debt
-44.08
-1861.2
-3192.75
-4577.8
BVPS
313.6
412.81
486.33
557.27

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
6,046.87
3,433.80
76.10%
3,264.44
3,244.19
0.62%
3,256.21
3,062.95
6.31%
3,387.55
2,506.70
35.14%
Expenses
3,687.32
2,831.88
30.21%
2,683.92
2,655.97
1.05%
2,695.18
2,558.61
5.34%
2,787.32
2,715.35
2.65%
EBITDA
2,359.55
601.91
292.01%
580.52
588.21
-1.31%
561.03
504.34
11.24%
600.23
-208.65
-
EBIDTM
39.02%
17.53%
17.78%
18.13%
17.23%
16.47%
17.72%
-8.32%
Other Income
200.63
39.42
408.95%
26.44
31.49
-16.04%
11.68
773.16
-98.49%
31.13
45.41
-31.45%
Interest
66.46
48.48
37.09%
58.23
39.58
47.12%
66.71
148.56
-55.10%
52.29
134.34
-61.08%
Depreciation
141.20
120.28
17.39%
129.93
117.79
10.31%
125.20
151.34
-17.27%
122.74
147.07
-16.54%
PBT
967.40
472.57
104.71%
95.58
462.33
-79.33%
7.97
530.83
-98.50%
456.33
-521.38
-
Tax
356.97
118.09
202.29%
48.61
122.10
-60.19%
3.59
1,769.47
-99.80%
108.30
-71.80
-
PAT
610.43
354.49
72.20%
46.97
340.24
-86.20%
4.38
-1,238.65
-
348.03
-449.58
-
PATM
10.10%
10.32%
1.44%
10.49%
0.13%
-40.44%
10.27%
-17.94%
EPS
21.63
12.55
72.35%
1.66
12.06
-86.24%
0.16
-43.17
-
12.33
-12.45
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
15,955.07
13,321.74
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
Net Sales Growth
30.27%
12.77%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
 
Cost Of Goods Sold
4,453.27
4,287.37
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
Gross Profit
11,501.80
9,034.37
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
GP Margin
72.09%
67.82%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
Total Expenditure
11,853.74
10,970.36
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
Power & Fuel Cost
-
131.40
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
120.47
% Of Sales
-
0.99%
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
Employee Cost
-
3,022.06
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
% Of Sales
-
22.69%
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
Manufacturing Exp.
-
987.39
1,012.86
633.51
784.63
638.74
669.50
725.16
648.59
546.75
956.59
% Of Sales
-
7.41%
8.57%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
General & Admin Exp.
-
1,457.32
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
% Of Sales
-
10.94%
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
Selling & Distn. Exp.
-
1,051.00
892.72
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
% Of Sales
-
7.89%
7.56%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
Miscellaneous Exp.
-
33.81
54.46
48.49
78.68
121.44
47.19
33.29
314.55
88.52
892.67
% Of Sales
-
0.25%
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
EBITDA
4,101.33
2,351.38
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
EBITDA Margin
25.71%
17.65%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
Other Income
269.88
113.72
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
20.00
Interest
243.69
207.06
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
178.88
Depreciation
519.07
486.01
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
234.28
PBT
1,527.28
1,772.03
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
Tax
517.47
352.07
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
300.94
Tax Rate
33.88%
25.16%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
PAT
1,009.81
1,047.09
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
PAT before Minority Interest
1,009.83
1,047.14
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
Minority Interest
0.02
-0.05
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
PAT Margin
6.33%
7.86%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
PAT Growth
201.64%
-
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
 
EPS
35.78
37.10
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29
26.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
8,849.44
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
Total Reserves
8,812.16
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
Non-Current Liabilities
109.35
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
512.70
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,967.02
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
Trade Payables
2,579.53
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
Other Current Liabilities
1,081.54
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
Short Term Borrowings
1,681.49
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
Short Term Provisions
624.46
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
134.03
Total Liabilities
14,925.44
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
Net Block
4,486.82
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
Gross Block
10,364.92
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
Accumulated Depreciation
5,878.10
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
Non Current Assets
5,629.98
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
Capital Work in Progress
834.83
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
Non Current Investment
56.35
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
17.20
Long Term Loans & Adv.
242.74
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
69.99
Other Non Current Assets
9.23
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
Current Assets
9,295.47
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
3,028.53
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
Sundry Debtors
3,341.95
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
Cash & Bank
1,705.23
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
Other Current Assets
1,219.76
178.21
316.61
297.46
1,371.54
1,147.78
1,312.40
1,391.61
1,273.61
986.77
Short Term Loans & Adv.
1,074.79
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
594.89
Net Current Assets
3,328.44
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
Total Assets
14,925.45
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
-827.60
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
PBT
1,399.21
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
Adjustment
982.01
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
Changes in Working Capital
-2,528.69
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
Cash after chg. in Working capital
-147.47
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-680.13
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
2.09
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
Net Fixed Assets
-307.30
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
Net Investments
-2,230.12
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
Others
2,539.51
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
Cash from Financing Activity
787.04
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
Net Cash Inflow / Outflow
-38.46
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
Opening Cash & Equivalents
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
Closing Cash & Equivalent
1,675.71
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
313.28
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
ROA
7.42%
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
ROE
12.56%
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
ROCE
16.16%
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
Fixed Asset Turnover
2.94
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
1.96
Receivable days
32.34
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
119.39
Inventory Days
34.46
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
67.68
Payable days
217.75
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
117.03
Cash Conversion Cycle
-150.94
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
Total Debt/Equity
0.25
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
Interest Cover
7.76
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28
6.84

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Glenmark Pharma’s arm launches Epinephrine Injection
    23rd Dec 2025, 11:00 AM

    Glenmark’s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label

    Read More
  • Glenmark Pharmaceuticals’ arm enters into agreement for Aumolertinib
    17th Dec 2025, 10:13 AM

    Glenmark Specialty S.A. has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co

    Read More
  • Glenmark Pharma’s arm to launch Leucovorin Calcium for Injection USP
    11th Dec 2025, 09:48 AM

    The Leucovorin Calcium for Injection, 350 mg/vial market achieved annual sales of around $16.8 million

    Read More
  • USFDA completes Pre-Approval Inspection at Glenmark Pharmaceuticals’ Aurangabad facility
    1st Dec 2025, 11:18 AM

    The inspection was carried out from November 24, 2025 to November 28, 2025, and concluded with zero 483 observations

    Read More
  • Glenmark Pharmaceuticals gets EIR with VAI status for USA manufacturing facility
    27th Nov 2025, 11:00 AM

    The commercial manufacturing at the Monroe site will now restart

    Read More
  • Glenmark launches Nebzmart GFB Smartules and Glenmark Airz FB Smartules
    25th Nov 2025, 12:10 PM

    The treatment was well tolerated and demonstrated a good safety profile, offering patients a simpler and more effective way to manage COPD

    Read More
  • Glenmark, Cosmo get market authorization for Winlevi from EC
    18th Nov 2025, 16:42 PM

    With receipt of this approval, Glenmark will initiate commercializing Winlevi across 15 countries in EU

    Read More
  • Glenmark Pharma - Quarterly Results
    15th Nov 2025, 00:00 AM

    Read More
  • Glenmark Pharmaceuticals’ arm gets NMPA’s nod for RYALTRIS Compound Nasal Spray
    10th Nov 2025, 17:23 PM

    Commercialization in China will be undertaken by Grand Pharmaceuticals Group under an exclusive licensing agreement

    Read More
  • Glenmark Pharma’s arm to launch Sodium Bicarbonate Injection USP
    4th Nov 2025, 10:23 AM

    Glenmark will begin distribution in November 2025

    Read More
  • Glenmark Pharma’s arm to launch Ropivacaine Hydrochloride Injection
    23rd Oct 2025, 11:12 AM

    Glenmark will begin distribution in November 2025

    Read More
  • Glenmark Pharmaceuticals’ arm recalls 13,824 Azelaic Acid Gel tubes in US market
    29th Sep 2025, 12:21 PM

    Glenmark Pharmaceuticals Inc has initiated the Class II nationwide recall on September 17, 2025

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.